Stelis Biopharma (Stelis), a vertically integrated biopharmaceutical company, announced that it has successfully concluded its Series B and Series C fund raise for a cumulative amount of US$ 195 million. Post money valuation for Stelis will be pegged at ~US$ 350m, underpinning the significant growth potential of the business, the release said. With the current […]
about people, work, and workplaces